Page 219 - Read Online

papillomaviruses to escape the host immune response. Curr Cancer J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S.
Drug Targets 2007;7:79-89. Global burden of human papillomavirus and related diseases. Vaccine
39. O’Brien PM, Saveria Campo M. Evasion of host immunity direct by 2012;30 Suppl 5:F12-23.
papillomavirus-encoded proteins. Virus Res 2002;88:103-17. 53. de Sanjosé S. Human Papillomavirus and cancer. Epidemiology and
40. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier prevention. 4th monograph of the Spanish Society of Epidemiology.
JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, Barcelona, Spain: Spanish Society of Epidemiology; 2006. p. 143-7.
de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart- 54. zur Hausen H. Papillomaviruses in the causation of human cancers - a
Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida brief historical account. Virology 2009;384:260-5.
M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, 55. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer
Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human
A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, papillomavirus is a necessary cause of invasive cervical cancer
Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, worldwide. J Pathol 1999;189:12-9.
Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, 56. Abramowitz L, Jacquard AC, Jaroud F, Haesebaert J, Siproudhis
Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar L, Pradat P, Aynaud O, Leocmach Y, Soubeyrand B, Dachez R,
M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein Riethmuller D, Mougin C, Pretet JL, Denis F. Human papillomavirus
J, Muñoz N, Bosch FX; Retrospective International Survey and genotype distribution in anal cancer in France: the EDiTH V study.
HPV Time Trends Study Group. Human papillomavirus genotype Int J Cancer 2011;129: 433-9.
attribution in invasive cervical cancer: a retrospective cross-sectional 57. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi
worldwide study. Lancet Oncol 2010;11:1048-56. S. Prevalence and type distribution of human papillomavirus in
41. Ryser MD, Myers ER, Durrett R. HPV Clearance and the Neglected carcinoma and intraepithelial neoplasia of the vulva, vagina and anus:
Role of Stochasticity. PLoS Comput Biol 2015;11:e1004113. a meta-analysis. Int J Cancer 2009;124:1626-36.
42. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander 58. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de
A, Lacey CJ, Kitchener HC, Einstein MH. Therapy of human Sanjosé S. Human papillomavirus prevalence and type distribution in
papillomavirus-related disease. Vaccine 2012;30 Suppl 5:F71-82. penile carcinoma. J Clin Pathol 2009;62:870-8.
43. Future II Study Group. Quadrivalent vaccine against human 59. St Guily JL, Jacquard AC, Prétet JL, Haesebaert J, Beby-Defaux A,
papillomavirus to prevent high-grade cervical lesions. N Engl J Med Clavel C, Agius G, Birembaut P, Okaïs C, Léocmach Y, Soubeyrand B,
2007;356:1915-27. Pradat P, Riethmuller D, Mougin C, Denis F. Human papillomavirus
44. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper genotype distribution in oropharynx and oral cavity cancer in France-
DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo -The EDiTH VI study. J Clin Virol 2011;51:100-4.
FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler 60. Grayson W, Rhemtula HA, Taylor LF, Allard U, Tiltman AJ. Detection
C, Barr E, Koutsky LA; Females United to Unilaterally Reduce of human papillomavirus in large cell neuroendocrine carcinoma of
Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent the uterine cervix: a study of 12 cases. J Clin Pathol 2002;55:108-14.
vaccine against human papillomavirus to prevent anogenital diseases. 61. Gravitt PE, Lacey JV Jr, Brinton LA, Barnes WA, Kornegay JR,
N Engl J Med 2007; 356:1928-43. Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel
45. Choi YH, Chapman R, Gay N, Jit M. Potential overestimation R, Schwartz PE, Zaino R, Hildesheim A. Evaluation of self-collected
of HPV vaccine impact due to unmasking of non-vaccine types: cervicovaginal cell samples for human papillomavirus testing by
quantification using a multi-type mathematical model. Vaccine polymerase chain reaction. Cancer Epidemiol Biomarkers Prev
2012;30:3383-8. 2001;10:95-100.
46. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila 62. Bouvard V, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F,
M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Benbrahim-Tallaa L, Guha N, Straif K; WHO International Agency for
Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen Research on Cancer Monograph Working Group. Carcinogenicity of
J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski malaria and of some polyomaviruses. Lancet Oncol 2012;13:339-40.
S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, 63. Egawa K. Do human papillomaviruses target epidermal stem cells?
Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley Dermatology 2003;207: 251-4.
TM, Barr E. The impact of quadrivalent human papillomavirus (HPV; 64. Schmitt A, Rochat A, Zeltner R, Borenstein L, Barrandon Y, Wettstein
types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection FO, Iftner T. The primary target cells of the high-risk cottontail
and disease due to oncogenic nonvaccine HPV types in sexually rabbit papillomavirus colocalize with hair follicle stem cells. J Virol
active women aged 16-26 years. J Infect Dis 2009;199:936-44. 1996;70:1912-22.
47. Aggarwal P. Cervical cancer: Can it be prevented? World J Clin 65. Kim K, Lambert PF. E1 protein of bovine papillomavirus 1 is not
Oncol 2014;5:775-80. required for the maintenance of viral plasmid DNA replication.
48. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of Virology 2002;293:10-4.
human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 66. Angeletti PC, Kim K, Fernandes FJ, Lambert PF. Stable replication
5:F123-38. of papillomavirus genomes in Saccharomyces cerevisiae. J Virol
49. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand 2002;76:3350-8.
H, Fairley CK. Quadrivalent human papillomavirus vaccination and 67. McBride AA. Replication and partitioning of papillomavirus
trends in genital warts in Australia: analysis of national sentinel genomes. Adv Virus Res 2008;72:155-205.
surveillance data. Lancet Infect Dis 2011;11:39-44. 68. Blakaj DM, Fernandez-Fuentes N, Chen Z, Hegde R, Fiser A, Burk
50. Future II Study Group. Quadrivalent vaccine against human RD, Brenowitz M. Evolutionary and biophysical relationships
papillomavirus to prevent high-grade cervical lesions. N Engl J Med among the papillomavirus E2 proteins. Front Biosci (Landmark Ed)
2007;356:1915-27. 2009;14:900-17.
51. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute 69. Chung CH, Gillison ML. Human papillomavirus in head and neck
risk of cervical intraepithelial neoplasia grade 3 or worse following cancer: its role in pathogenesis and clinical implications. Clin Cancer
human papillomavirus infection: role of persistence. J Natl Cancer Res 2009;15:6758-62.
Inst 2010;102:1478-88. 70. Valencia C, Bonilla-Delgado J, Oktaba K, Ocádiz-Delgado
52. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent R, Gariglio P, Covarrubias L. Human papillomavirus E6/E7

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ June 15, 2016 ¦ 209